Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Total net revenue		$ 107,238	$ 114,760	$ 211,130	$ 211,253
Total cost of revenue	[1]	71,336	71,793	135,735	133,689
Research and development	[2]	15,281	14,641	29,294	28,733
Products
Total net revenue	[3]	51,538	63,269	104,888	107,892
Total cost of revenue		34,333	39,248	70,032	68,098
Services
Total net revenue	[4]	55,700	51,491	106,242	103,361
Total cost of revenue		37,003	32,545	65,703	65,591
Revenue from Joint Venture
Total cost of revenue		11,102	9,916	26,373	15,823
Research and development		67	487	199	1,266
Revenue from Joint Venture | Products
Total net revenue		17,890	16,715	39,842	25,584
Revenue from Joint Venture | Services
Total net revenue		$ 4,134	$ 2,494	$ 6,988	$ 5,451

[1] Includes cost of revenue from sales to the joint venture, an equity method investment, of $11,102 and $26,373 during the three and six months ended December 31, 2023 and $9,916 and $15,823 during the three and six months ended December 31, 2022. respectively.

[2] Includes charge backs to the joint venture, an equity method investment, related to research and development of $67 and $199 during the three and six months ended December 31, 2023 and $487 and $1,266 during the three and six months ended December 31, 2022, respectively.

[3] Includes sales of products to the joint venture, an equity method investment, of $17,890 and $39,842 during the three and six months ended December 31, 2023 and $16,715 and $25,584 during the three and six months ended December 31, 2022, respectively. See Note 13.

[4] Includes sales of services to the joint venture, an equity method investment, of $4,134 and $6,988 during the three and six months ended December 31, 2023 and $2,494 and $5,451 during the three and six months ended December 31, 2022, respectively. See Note 13.